Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Patent
1997-10-30
1999-11-09
Saucier, Sandra E.
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
530381, 530384, C12N 974, A61K 3514
Patent
active
059812540
ABSTRACT:
This invention relates to a process for preparing biological glue components from a plasma pool which combines high recovery, quality product and viral safety. In first instance, a triple viral inactivated product comprising fibrogen, fibronectin and FXIII is obtained by treating a concentrate thereof first with a viricide solvent/detergent solution, second with viral nanofiltration, and third with heat. The recovery of a good quality product is not compromised by the process of the invention. In second instance, the same steps are reproduced for obtaining a triple viral safe thrombin product. In that case, a known proprietary process has been improved to increase the recovery of active thrombin by about two fold. One of the steps which increase the yield of thrombin is the dilution of the prothrombin solution with water 4 volumes to 1 volume prothrombin prior to acid precipitation.
REFERENCES:
patent: 5143838 (1992-09-01), Kraus et al.
patent: 5290918 (1994-03-01), Bui-Khac
patent: 5304372 (1994-04-01), Michalski et al.
patent: 5506127 (1996-04-01), Proba et al.
Morris & Morris, Separation Methods in Biochemistry, Second Ed., Pitman Publishing, 1976, pp. 300-303.
Ahern, T.J. & A.M. Klibanov, (1985). The Mechanism of Irreversible Enzyme Inactivation at 100.degree. C; Science, 228:1280-1284.
Burnout, T. & M. Burnouf-Radosevich (1993) "Strategy of Virus Removal/Inactivation of Plasma-Derived Products: Interest of Nanofiltration. . . "; JAACT Proceedings, Manuscript supplied by T. Burnouf.
Dietrich, S.L., et al. (1990) "Transmission of Human Immunodeficiency Virus Type 1 by Dry-Heated Clotting Factor Concentrates"; Vox Sang; 59:129-135.
Harbour, C., et. al. (1991) "Viral Contamination of Therapeutic Proteins: a Challenge for Downstream Processing"; Australian Journal of Biotechnology. 5(2):81-86.
Heimburger, N. & H.E. Karges (1989) "Strategies to Produce Virus-Safe Blood Derviratives"; Virus Inactivation in Plasma Products; Curr Stud Hematol Blood Transfus; Morgenthaler J-J (ed): No. 56, pp. 23-33.
Horowitz, B. (1989) "Investigations into the Application of Tri(n-Buryl)Phosphate/Detergent Mixtures to Blood Derivatives"; Morgenthaler J-J (ed): Virus Inactivation in Plasma Products; Curr Stud Hematol Blood Transfus; Basel, Karger, 1989, No. 56, pp. 83-96.
Kuhnl, P. et al. (1989) "Reduction of Virus Load in Blood Donations by Screening Methods"; Morgenthaler J-J (ed): Virus Inactivation in Plasma Products; Curr Stud Hematol Blood Transfus; Basel, Karger, 1989, No. 56, pp. 9-22.
Loomis, E.C. & W.H. Seegers (1944) "Purified Prothrombin: Factors which Influence Its Activation", pp. 265-271.
Manabe S. (1992) "Virus Removal and Inactivation in Process Validation"; Animal Cell Technology: Basics & Applied Aspects (Murakami, H. Shirahata, S. Tachibana, H., eds.), pp. 15-30.
Miletich, J.P. et al., (1980) The Synthesis of Sulfated Dextran Beads for Isolation of Human Plasma Coagulation Factors II, IX, and X.sup.1 ; Analytical Biochemistry 105:304-310.
Piszkiewicz, D. et al. (1989) "Virus Inactivation by Heat Treatment of Lyophilized Coagulation Factor Concentrates" Virus Inactivation in Plasma Products; Curr Stud Hematol Blood Transfus. Basel,Karger, 1989, No. 56, pp. 44-54.
Rubinstein, AiI. et al. (1991) "Combined Solvent-Detergent and 100.degree. C. (Boiling) Sterilizing Dry-Heat Treatment of Factor VIII Concentrates to Assure Sterility" Vox Sang, 60:60.
Schilt, U. (1989) "Overview of Viruses Relevant to Blood Transfusion"; Virus Inactivation in Plasma Products; Curr Stud Hematol Blood Transfus. Basel,Karger, No. 56, pp. 1-8.
Winkelman, L. et al. (1989) "Severe Heat Treatment of Lyophilised Coagulation Factors"; Virus Inactivation in Plasma Products; Curr Stud Hematol Blood Transfus. Basel,Karger; No. 56, pp. 55-69.
Haemacure Corporation
Saucier Sandra E.
LandOfFree
Process for producing thrombin from plasma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for producing thrombin from plasma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for producing thrombin from plasma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1454448